Proteoglycan degradation by a chondrocyte metalloprotease: Effects of synthetic protease inhibitors
Synthetic inhibitors of a chondrocyte metalloprotease (CMP) were assessed for potency. Proteoglycan core protein was used as substrate. The ic 50 values were between 2 × 10 −6 and 7 × 10 −6 M for two types of inhibitors, thiol tripeptides and N-carboxyalkyl peptides. Hydroxamic acid peptides were mo...
Gespeichert in:
Veröffentlicht in: | Biochemical pharmacology 1987-04, Vol.36 (7), p.995-1002 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1002 |
---|---|
container_issue | 7 |
container_start_page | 995 |
container_title | Biochemical pharmacology |
container_volume | 36 |
creator | Caputo, Claudia B. Wolanin, Donald J. Roberts, Richard A. Sygowski, Linda A. Patton, Steven P. Caccese, Robert G. Shaw, Andrew DiPasquale, Gene |
description | Synthetic inhibitors of a chondrocyte metalloprotease (CMP) were assessed for potency. Proteoglycan core protein was used as substrate. The
ic
50 values were between 2 × 10
−6 and 7 × 10
−6 M for two types of inhibitors, thiol tripeptides and
N-carboxyalkyl peptides. Hydroxamic acid peptides were more potent, with
ic
50 values of 3.2 × 10
−8 to 6.0 × 10
−8M. These results confirm inhibitory concentrations reported using a proteoglycan-polyacrylamide bead assay. The slopes of the doseresponse curves for the thiol compounds were steeper than the slopes for the other two types of compounds. All of the culture media tested inhibited CMP to some extent. Some media also interfered with inhibitor activity. In Ham's F10 nutrient medium, minimum CMP inhibition occurred, and all four hydroxamic acid peptides retained their activity for 1–2 days at 37°. One thiol peptide compound assayed lost activity in 1 hr in thiocyanate-treated serum. All four hydroxamic acid peptides assayed retained activity in thiocyanate-treated serum after 3 days at 37°. The hydroxamic acid peptides may provide a way to block endogenous CMP activity
in vivo and to assess the role of CMP in normal and experimentally altered cartilage. They are more potent than other known CMP inhibitors. They retain activity in culture media and serum conditions used for
in vivo and
in vitro tests of CMP activity and toxicity. |
doi_str_mv | 10.1016/0006-2952(87)90405-9 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_3551961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0006295287904059</els_id><sourcerecordid>3551961</sourcerecordid><originalsourceid>FETCH-LOGICAL-e290t-9413ef288fc466fbdce3b164043f6b78bdf1a69a52fddbb9bb8b42815d0c1ed53</originalsourceid><addsrcrecordid>eNo9UctKBDEQDKLo-vgDhRw86GE0mUcm8SDIsj5gQQ96Dnl03MjsZEmiMH_vjK6emu6qbrqqEDql5IoSyq4JIawoRVNe8PZSkJo0hdhBM8rbahwzvotm_5QDdJjSx9RyRvfRftU0VDA6Q-YlhgzhvRuM6rGF96isyj70WA9YYbMKvY3BDBnwGrLqurCZFlSCG7xwDkxOODichj6vIHuD_2Ds-5XXPoeYjtGeU12Ck209Qm_3i9f5Y7F8fnia3y0LKAXJhahpBa7k3JmaMaetgUpTVpO6cky3XFtHFROqKZ21Wgutua5LThtLDAXbVEfo7Pfu5lOvwcpN9GsVB7kVO-LnW1wlozoXVW98-qe1tajblo-0218ajL9-eYgyGQ-9AevjqFfa4CUlcspATo7KyWDJW_mTgRTVNy1zer8</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Proteoglycan degradation by a chondrocyte metalloprotease: Effects of synthetic protease inhibitors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Caputo, Claudia B. ; Wolanin, Donald J. ; Roberts, Richard A. ; Sygowski, Linda A. ; Patton, Steven P. ; Caccese, Robert G. ; Shaw, Andrew ; DiPasquale, Gene</creator><creatorcontrib>Caputo, Claudia B. ; Wolanin, Donald J. ; Roberts, Richard A. ; Sygowski, Linda A. ; Patton, Steven P. ; Caccese, Robert G. ; Shaw, Andrew ; DiPasquale, Gene</creatorcontrib><description>Synthetic inhibitors of a chondrocyte metalloprotease (CMP) were assessed for potency. Proteoglycan core protein was used as substrate. The
ic
50 values were between 2 × 10
−6 and 7 × 10
−6 M for two types of inhibitors, thiol tripeptides and
N-carboxyalkyl peptides. Hydroxamic acid peptides were more potent, with
ic
50 values of 3.2 × 10
−8 to 6.0 × 10
−8M. These results confirm inhibitory concentrations reported using a proteoglycan-polyacrylamide bead assay. The slopes of the doseresponse curves for the thiol compounds were steeper than the slopes for the other two types of compounds. All of the culture media tested inhibited CMP to some extent. Some media also interfered with inhibitor activity. In Ham's F10 nutrient medium, minimum CMP inhibition occurred, and all four hydroxamic acid peptides retained their activity for 1–2 days at 37°. One thiol peptide compound assayed lost activity in 1 hr in thiocyanate-treated serum. All four hydroxamic acid peptides assayed retained activity in thiocyanate-treated serum after 3 days at 37°. The hydroxamic acid peptides may provide a way to block endogenous CMP activity
in vivo and to assess the role of CMP in normal and experimentally altered cartilage. They are more potent than other known CMP inhibitors. They retain activity in culture media and serum conditions used for
in vivo and
in vitro tests of CMP activity and toxicity.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/0006-2952(87)90405-9</identifier><identifier>PMID: 3551961</identifier><identifier>CODEN: BCPCA6</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Animals ; Biological and medical sciences ; Bones, joints and connective tissue. Antiinflammatory agents ; Cartilage, Articular - enzymology ; Cells, Cultured ; Culture Media ; Drug Stability ; Endopeptidases ; Kinetics ; Medical sciences ; Metalloendopeptidases ; Pharmacology. Drug treatments ; Protease Inhibitors - pharmacology ; Proteoglycans - metabolism ; Rabbits</subject><ispartof>Biochemical pharmacology, 1987-04, Vol.36 (7), p.995-1002</ispartof><rights>1987</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0006295287904059$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7494778$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3551961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caputo, Claudia B.</creatorcontrib><creatorcontrib>Wolanin, Donald J.</creatorcontrib><creatorcontrib>Roberts, Richard A.</creatorcontrib><creatorcontrib>Sygowski, Linda A.</creatorcontrib><creatorcontrib>Patton, Steven P.</creatorcontrib><creatorcontrib>Caccese, Robert G.</creatorcontrib><creatorcontrib>Shaw, Andrew</creatorcontrib><creatorcontrib>DiPasquale, Gene</creatorcontrib><title>Proteoglycan degradation by a chondrocyte metalloprotease: Effects of synthetic protease inhibitors</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>Synthetic inhibitors of a chondrocyte metalloprotease (CMP) were assessed for potency. Proteoglycan core protein was used as substrate. The
ic
50 values were between 2 × 10
−6 and 7 × 10
−6 M for two types of inhibitors, thiol tripeptides and
N-carboxyalkyl peptides. Hydroxamic acid peptides were more potent, with
ic
50 values of 3.2 × 10
−8 to 6.0 × 10
−8M. These results confirm inhibitory concentrations reported using a proteoglycan-polyacrylamide bead assay. The slopes of the doseresponse curves for the thiol compounds were steeper than the slopes for the other two types of compounds. All of the culture media tested inhibited CMP to some extent. Some media also interfered with inhibitor activity. In Ham's F10 nutrient medium, minimum CMP inhibition occurred, and all four hydroxamic acid peptides retained their activity for 1–2 days at 37°. One thiol peptide compound assayed lost activity in 1 hr in thiocyanate-treated serum. All four hydroxamic acid peptides assayed retained activity in thiocyanate-treated serum after 3 days at 37°. The hydroxamic acid peptides may provide a way to block endogenous CMP activity
in vivo and to assess the role of CMP in normal and experimentally altered cartilage. They are more potent than other known CMP inhibitors. They retain activity in culture media and serum conditions used for
in vivo and
in vitro tests of CMP activity and toxicity.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Cartilage, Articular - enzymology</subject><subject>Cells, Cultured</subject><subject>Culture Media</subject><subject>Drug Stability</subject><subject>Endopeptidases</subject><subject>Kinetics</subject><subject>Medical sciences</subject><subject>Metalloendopeptidases</subject><subject>Pharmacology. Drug treatments</subject><subject>Protease Inhibitors - pharmacology</subject><subject>Proteoglycans - metabolism</subject><subject>Rabbits</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UctKBDEQDKLo-vgDhRw86GE0mUcm8SDIsj5gQQ96Dnl03MjsZEmiMH_vjK6emu6qbrqqEDql5IoSyq4JIawoRVNe8PZSkJo0hdhBM8rbahwzvotm_5QDdJjSx9RyRvfRftU0VDA6Q-YlhgzhvRuM6rGF96isyj70WA9YYbMKvY3BDBnwGrLqurCZFlSCG7xwDkxOODichj6vIHuD_2Ds-5XXPoeYjtGeU12Ck209Qm_3i9f5Y7F8fnia3y0LKAXJhahpBa7k3JmaMaetgUpTVpO6cky3XFtHFROqKZ21Wgutua5LThtLDAXbVEfo7Pfu5lOvwcpN9GsVB7kVO-LnW1wlozoXVW98-qe1tajblo-0218ajL9-eYgyGQ-9AevjqFfa4CUlcspATo7KyWDJW_mTgRTVNy1zer8</recordid><startdate>19870401</startdate><enddate>19870401</enddate><creator>Caputo, Claudia B.</creator><creator>Wolanin, Donald J.</creator><creator>Roberts, Richard A.</creator><creator>Sygowski, Linda A.</creator><creator>Patton, Steven P.</creator><creator>Caccese, Robert G.</creator><creator>Shaw, Andrew</creator><creator>DiPasquale, Gene</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19870401</creationdate><title>Proteoglycan degradation by a chondrocyte metalloprotease: Effects of synthetic protease inhibitors</title><author>Caputo, Claudia B. ; Wolanin, Donald J. ; Roberts, Richard A. ; Sygowski, Linda A. ; Patton, Steven P. ; Caccese, Robert G. ; Shaw, Andrew ; DiPasquale, Gene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e290t-9413ef288fc466fbdce3b164043f6b78bdf1a69a52fddbb9bb8b42815d0c1ed53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Cartilage, Articular - enzymology</topic><topic>Cells, Cultured</topic><topic>Culture Media</topic><topic>Drug Stability</topic><topic>Endopeptidases</topic><topic>Kinetics</topic><topic>Medical sciences</topic><topic>Metalloendopeptidases</topic><topic>Pharmacology. Drug treatments</topic><topic>Protease Inhibitors - pharmacology</topic><topic>Proteoglycans - metabolism</topic><topic>Rabbits</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caputo, Claudia B.</creatorcontrib><creatorcontrib>Wolanin, Donald J.</creatorcontrib><creatorcontrib>Roberts, Richard A.</creatorcontrib><creatorcontrib>Sygowski, Linda A.</creatorcontrib><creatorcontrib>Patton, Steven P.</creatorcontrib><creatorcontrib>Caccese, Robert G.</creatorcontrib><creatorcontrib>Shaw, Andrew</creatorcontrib><creatorcontrib>DiPasquale, Gene</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caputo, Claudia B.</au><au>Wolanin, Donald J.</au><au>Roberts, Richard A.</au><au>Sygowski, Linda A.</au><au>Patton, Steven P.</au><au>Caccese, Robert G.</au><au>Shaw, Andrew</au><au>DiPasquale, Gene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proteoglycan degradation by a chondrocyte metalloprotease: Effects of synthetic protease inhibitors</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>1987-04-01</date><risdate>1987</risdate><volume>36</volume><issue>7</issue><spage>995</spage><epage>1002</epage><pages>995-1002</pages><issn>0006-2952</issn><eissn>1873-2968</eissn><coden>BCPCA6</coden><abstract>Synthetic inhibitors of a chondrocyte metalloprotease (CMP) were assessed for potency. Proteoglycan core protein was used as substrate. The
ic
50 values were between 2 × 10
−6 and 7 × 10
−6 M for two types of inhibitors, thiol tripeptides and
N-carboxyalkyl peptides. Hydroxamic acid peptides were more potent, with
ic
50 values of 3.2 × 10
−8 to 6.0 × 10
−8M. These results confirm inhibitory concentrations reported using a proteoglycan-polyacrylamide bead assay. The slopes of the doseresponse curves for the thiol compounds were steeper than the slopes for the other two types of compounds. All of the culture media tested inhibited CMP to some extent. Some media also interfered with inhibitor activity. In Ham's F10 nutrient medium, minimum CMP inhibition occurred, and all four hydroxamic acid peptides retained their activity for 1–2 days at 37°. One thiol peptide compound assayed lost activity in 1 hr in thiocyanate-treated serum. All four hydroxamic acid peptides assayed retained activity in thiocyanate-treated serum after 3 days at 37°. The hydroxamic acid peptides may provide a way to block endogenous CMP activity
in vivo and to assess the role of CMP in normal and experimentally altered cartilage. They are more potent than other known CMP inhibitors. They retain activity in culture media and serum conditions used for
in vivo and
in vitro tests of CMP activity and toxicity.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>3551961</pmid><doi>10.1016/0006-2952(87)90405-9</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-2952 |
ispartof | Biochemical pharmacology, 1987-04, Vol.36 (7), p.995-1002 |
issn | 0006-2952 1873-2968 |
language | eng |
recordid | cdi_pubmed_primary_3551961 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Cartilage, Articular - enzymology Cells, Cultured Culture Media Drug Stability Endopeptidases Kinetics Medical sciences Metalloendopeptidases Pharmacology. Drug treatments Protease Inhibitors - pharmacology Proteoglycans - metabolism Rabbits |
title | Proteoglycan degradation by a chondrocyte metalloprotease: Effects of synthetic protease inhibitors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T03%3A14%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proteoglycan%20degradation%20by%20a%20chondrocyte%20metalloprotease:%20Effects%20of%20synthetic%20protease%20inhibitors&rft.jtitle=Biochemical%20pharmacology&rft.au=Caputo,%20Claudia%20B.&rft.date=1987-04-01&rft.volume=36&rft.issue=7&rft.spage=995&rft.epage=1002&rft.pages=995-1002&rft.issn=0006-2952&rft.eissn=1873-2968&rft.coden=BCPCA6&rft_id=info:doi/10.1016/0006-2952(87)90405-9&rft_dat=%3Cpubmed_pasca%3E3551961%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/3551961&rft_els_id=0006295287904059&rfr_iscdi=true |